Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Monotherapy and Add-on Therapy in Adolescents with Type 2 Diabetes
KCT0000711Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2012
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Feb 2012; status: terminated.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0000711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000711.